SCHEMBL8013133

SCHEMBL8013133

COc1cc2c(cc1OC)C(=O)/C(=C\C1CCN(Cc3ccccc3)CC1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ACHE P22303 13/20 1.00
BACE1 P56817 2/20 1.00
BCHE P06276 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506653 1.00 ACHE (1.00) ACHEBACE1BCHE
SCHEMBL1877163 1.00 ACHE (1.00) ACHEBACE1BCHE
SCHEMBL3086109 1.00 ACHE (1.00) ACHEBACE1BCHE
SCHEMBL29506655 1.00 ACHE (1.00) ACHEBACE1BCHE
Hydrochloric Acid SCHEMBL4205699 0.99 ACHE (0.98) ACHEBACE1BCHE
Hydrochloric Acid SCHEMBL29506654 0.99 ACHE (0.98) ACHEBACE1BCHE
SCHEMBL24401463 0.94 ACHE (0.89) ACHEBACE1BCHE
SCHEMBL14601859 0.94 ACHE (0.89) ACHEBACE1BCHE
SCHEMBL4200014 0.93 ACHE (0.87) ACHEBACE1BCHE
SCHEMBL6857051 0.93 ACHE (0.87) ACHEBACE1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112641773-A Composition containing heterocyclic compound and use thereof 黄泳华 2021-04-13 CN claimed
CN-111265524-A Compositions containing mixtures of indene or indane derivatives and uses thereof 黄泳华 2020-06-12 CN claimed
CN-112641773-A Composition containing heterocyclic compound and use thereof 黄泳华 2021-04-13 CN disclosed
CN-111265524-A Compositions containing mixtures of indene or indane derivatives and uses thereof 黄泳华 2020-06-12 CN disclosed
US-9249098-B2 Derivatives of donepezil CHENG XUEHENG (US) 2016-02-02 US disclosed
US-9249098-B2 Derivatives of donepezil CHENG XUEHENG (US) 2016-02-02 US disclosed
US-20150225343-A1 NOVEL DERIVATIVES OF DONEPEZIL CHENG XUEHENG (US) 2015-08-13 US disclosed
US-20150225343-A1 NOVEL DERIVATIVES OF DONEPEZIL CHENG XUEHENG (US) 2015-08-13 US disclosed
WO-2014008629-A1 NOVEL DERIVATIVES OF DONEPEZIL SUZHOU SHANGZHI BIOTECH LIMITED (CN) 2014-01-16 WO disclosed
WO-2012170599-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2012-12-13 WO disclosed
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS INC. (US) 2011-12-29 US disclosed
US-20100143505-A1 INDANONE INHIBITORS OF ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-10 US disclosed
US-20100113793-A1 Process for the Preparation of Highly Pure Donepezil IND-SWIFT LABORATORIES LIMITED (IN) 2010-05-06 US disclosed
US-20100113793-A1 Process for the Preparation of Highly Pure Donepezil IND-SWIFT LABORATORIES LIMITED (IN) 2010-05-06 US disclosed
WO-2009084030-A2 IMPROVED PROCESS FOR THE PREPARATION OF (1-BENZYL-4-(5,6,- DIMETHOXYIND ANONE-2-YL)METHYLPIPERIDINE) HYDROCHLORIDE-FORM III NEULAND LABORATORIES LTD. (IN) 2009-07-09 WO disclosed
WO-2008126995-A1 A PROCESS FOR PREPARING INTERMEDIATE OF DONEPEZIL DONG WHA PHARM. IND. CO., LTD. (KR) 2008-10-23 WO disclosed
EP-1911745-A1 PROCESS FOR PRODUCING 1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANONE)-2-YLIDENE]METHYLPIPERIDINE Eisai R&D Management Co., Ltd. (JP) 2008-04-16 EP disclosed
WO-2007108011-A2 PROCESS FOR THE PREPARATION OF HIGHLY PURE DONEPEZIL IND-SWIFT LABORATORIES LIMITED (IN) 2007-09-27 WO disclosed
US-20070135644-A1 PROCESS FOR MAKING DONEPEZIL SYNTHON BV (NL) 2007-06-14 US disclosed
US-20070135644-A1 PROCESS FOR MAKING DONEPEZIL SYNTHON BV (NL) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 ACHE 18/4885BACE1 233/4885BCHE 42/4885
US-20100113793-A1 Process for the Preparation of Highly Pure Donepezil PSEN1, ACHE, PSEN2 ACHE 2/4885BACE1 17/4885BCHE 5/4885
US-20100143505-A1 INDANONE INHIBITORS OF ACETYLCHOLINESTERASE ACHE, BCHE, CHAT ACHE 1/4885BACE1 11/4885BCHE 2/4885
US-20150225343-A1 NOVEL DERIVATIVES OF DONEPEZIL ACHE, BCHE, HNMT ACHE 1/4885BACE1 7/4885BCHE 2/4885
US-20070135644-A1 PROCESS FOR MAKING DONEPEZIL MAOA, ACHE, CHAT ACHE 2/4885BACE1 57/4885BCHE 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.